Renaissance Technologies’s Aimmune Therapeutics AIMT Stock Holding History

Renaissance Technologies’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-108,900	Closed	-$1.57M	–	3916
2020 Q1	$1.57M	Buy	+108,900	New	+$2.78M	﹤0.01%	2187
2018 Q4	–	Sell	-29,800	Closed	-$813K	–	3732
2018 Q3	$813K	Sell	29,800 -28,500	-49%	-$806K	﹤0.01%	2685
2018 Q2	$1.57M	Buy	+58,300	New	+$1.78M	﹤0.01%	2397
2017 Q1	–	Sell	-102,700	Closed	-$2.1M	–	3497
2016 Q4	$2.1M	Buy	+102,700	New	+$2.1M	﹤0.01%	2206

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies's AIMT Position: Q2 2020 in Review

Renaissance Technologies sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 108,900 shares — an estimated $1.57M sold.

Renaissance Technologies first reported a position in AIMT in Q4 2016 and held it in 4 quarters. The position peaked at $2.1M in Q4 2016. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

Renaissance Technologies reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
Renaissance Technologies sold 108,900 Aimmune Therapeutics shares in Q2 2020, an estimated $1.57M.
Renaissance Technologies first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 4 quarters.
Renaissance Technologies's Aimmune Therapeutics position peaked at $2.1M in Q4 2016.
165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.